Global Point of Care Testing (POCT) Devices Market Expected to reach USD 20 billion by 2024, says Study

A new market study, titled “Global Point of Care Testing (POCT) Devices Market Outlook 2024: Global Opportunity and Demand Analysis, Market Forecast, 2016-2024”, has been featured on WiseGuyReports.

Market Overview

The point of care testing (POCT) device in healthcare sector focuses on value rather than test volume and reimbursement issues that minimize tests to the optimal point where outcomes won’t suffer while cost efficiencies are gained. The global point of care testing (POCT) diagnostics market is estimated to reach USD 20 billion by the year 2024. Upcoming technological advancements in smart phones, biosensors, lab-on-a-chip and wearable devices tend to transform the whole spectrum of POCT market. The driving force behind these innovations in healthcare is to provide ease of diagnosis where the patient is seen at home. In future POC can be the part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine. On the basis of settings and operating the POCT devices there are two categories: Non professional settings (scenes, non-medical facilities, home, etc) performed by non-traditional operators and professionals settings (Clinics, hospitals, lab, etc) performed by traditional operators. In Mexico, POCT devices are utilized in self monitoring, over the counter and emergency departments.

One of the driving factor for the growth of POCT devices market is its increasing penetration in developed countries e.g. In most of the European countries like Spain and the UK, the reimbursement system is the reason for augmented demand for POCT devices. The manufacturers are also focusing towards the advancement in point of care devices in terms of design and functionality.

Market Segmentation

• By Systems Basis

 Blood Gas Family

 Cardiac

 Diabetes

 Urinalysis

 Informatics

• By Clinical Specialties & Diseases

 Cardiology

 Critical Care

 Diabetes

 Endocrinology

 Liver Diseases

 Maternal Fetal

 Neonatology

• By Areas of Use

 Inpatient Care (Operation Theater, Intensive care ward, Emergency departments, etc)

 Outpatient Care (Medical Practice, House Visits, etc)

 Special Areas (Sport medicine, civil protection and Military)

 Patient self-monitoring (Glucose monitoring, Anti-coagulant monitoring)

 Relative Medical Indication (Sport studio, Tests from pharmacy)

• By End User

 Hospitals

 Clinics

 Diagnostic Labs

 Home Care

• By Region

 North America (US, Canada) {Market Share (%), Market Size (USD Million), Product Sales (Units)}

 Europe (UK, France, Italy, Germany, Spain, Hungary, Sweden, Russia, Poland and Rest of Europe) {Market Share (%), Market Size (USD Million), Product Sales (Units)}

 Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Million), Product Sales (Units)}

 Latin America (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Million), Product Sales (Units)}

 Asia Pacific (China, Japan, India, Singapore, South Korea, Australia, New Zealand and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Million), Product Sales (Units)}

• Rest of the World{Market Share (%), Market Size (USD Million), Product Sales (Units)}

Request Sample Report at https://www.wiseguyreports.com/sample-request/2111656-global-point-of-care-testing-poct-devices-market-outlook-2024-global

Market Size and Forecast (2016-2024)

The emerging healthcare industry represents more than USD1.3 trillion and is growing at the rate of 6.8% across the globe. Out of which global medical device market in the year 2016 reached USD315 billion on the back of rapid advancement in medical devices technology. However, winning market share in the traditional markets (Western Europe, and the US) will remain difficult due to growing regulatory scrutiny and pricing pressures. German POCT devices market is almost USD 1.2 billion. In 2013, North America (US, Canada and Mexico) held the largest share of the global POC diagnostics market because of huge and increasing addressable patient population base. The US will remain the largest producer and consumer of medical devices, accounting for 26% of the global market. Similarly, the demand growth for medical devices in Western Europe is expected to stagnate, constrained by the declining expenditure from the budget-constrained healthcare industry. Asia Pacific, however, presents unique opportunities for medical device producers. For instance, China’s and India’s healthcare service revenues are advanced by 12% and 9%, respectively, in 2016 alone, resulting in a large number of new hospital construction projects and thus soaring demand for medical and surgical equipment.

POCT devices contribute 7-8% in the medical device market. However, number of healthcare personnel stands at 7.2 million globally today, as the number of skilled healthcare workers decreases, there is a shift toward accurate, intuitive tests that can be operated by less skilled personnel and patients. POCT is one of the innovations that can potentially have impact on quality of care as well as on system redesign and a more patient centered approach to care.

Test volume wise US makes up majority of the market. Due to implementation CLIA and FDA standards, US is the most amenable to specialized POC. Although Europe is growing faster than US due to evolution of more and more physician office labs (POL’s). Japan being highly centralized form of healthcare does not prefer POCT in POLs. However, POCT is preferred in emergency and critical care in Japan. The need of advance diagnosis is rising in developed nations as the awareness towards diagnostics is rising. Moreover, rising number of diagnostics labs in developing countries further expected to foster the demand for point of care devices in near future.

Key Trends and Growth Drivers

Diabetes represents 67% of the market share and is the primary driver of POCT market followed by other highly growing segments include cardiac coagulations, infectious disease and blood gas with great optimization of care processes. MDx based tests for infectious diseases such as MRSA and Sepsis have significant growth potential as they are POC oriented.

Restraints

• Due to multiple testing platforms and manual POCT methods, possibility of complexity of data management and oversight rises. The Philippines and Taiwan are planning national guidelines for POCT.
• Investment costs for a single POCT assay systems may seem low but POCT devices are limited to one or few assays only and do not produce a fraction of results during their life cycle compared with instruments in the core laboratory

Key Findings

• Roche, Biosite, Bayer, Inverness and Abbott lead the market.
• Roche leads the Coagulation segment along International Technidyne Corporation.
• Inverness owns the key patents to lateral flow based infectious disease testing; players such as Quidel are gaining the market through flu and other respiratory diseases.
• POC oriented Molecular Dx offerings from companies like Cepheid may gain traction when hospitals become more vigilant in screening MRSA.
• There is scope for new entrants in growing segments such as infectious and cardiac areas where new technologies are like to take market.
• Taiwan has good number of local players (K-Mac, TaiDoc, etc)

Advancements Taking Place

• In Asia, LamdaGen Taiwan will commercialize a number of powerful, single-step, rapid and precisely quantitated POCT diagnostics with sensitivities into the low to sub-femtomolar range using a single sample drop.
• With awareness of POCT growing, many companies are actively developing next-generation products. For example, the Shiga Prefecture Industrial Support Center is working together with various companies and universities in a joint effort to develop a POCT system capable of delivering sophisticated diagnoses from a single drop of blood.
• At present there are still no devices offering easy testing of oral bacterial counts; the development goal is to deliver a POCT device that uses electrical measurements to rapidly assess pathogen levels. Dentists can use the device for diagnosis during regular dental visits, while dental hygienists, nurses, and other professionals can use it to assess periodontal disease risks on the spot.
• Another joint project—involving Immuno Probe, Fukaekasei, Kyushu University, Tokyo Dental College, Panasonic Healthcare, and others—is engaged in developing an intraoral bacteriological device suitable for diagnosing periodontal disease.

Key Players

• Abbott/i-STAT

 Synopsis

 Business Strategy

 Product Portfolio

 SWOT Analysis

• Bayer
• Biosite
• bioMerieux
• Cholestech
• Instrumentation Laboratory
• Inverness
• International Technidyne Corporation
• Meridian
• Nova Biomedical
• Roche
• Quidel

 

Table of Contents

1. Parent Market Synopsis
2. Executive Summary
3. Research Methodology
4. Regional Opportunity Analysis on the basis of Competitors
5. Global Point of Care Testing (POCT) Market Size (USD Billion) and Forecast Analysis, 2016-2024
6. Market Dynamics: Growth Drivers, Restraints and Opportunities
7. Global POCT Market Segmentation
8. Competitive Outlook
9. Porter’s Five Force Model
10. Market Landscape: Competition and Beyond
11. Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem
12. Expert Analysis
13. Concluding Remarks

 

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

 

Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com       

Ph: +1-646-845-9349 (US)                          

Ph: +44 208 133 9349 (UK)